Navigating the US Pharmaceutical Landscape: A New Initiative for Swiss Startups

A collaborative effort spearheaded by Basel-Bayer, in conjunction with Superlab Suisse, Curie.bio, Goodwin, and Danforth Advisors, has given rise to the “Bayer Co.Lab Connect-Basel” programme. This initiative is specifically designed to assist early-stage Swiss startups in successfully navigating the complexities of the United states’ pharmaceutical ecosystem.

While Europe remains a hub for pharmaceutical innovation, the United States represents a pivotal market for accelerating the growth and adoption of new medications.Early entry into the US market can significantly impact a startupS access to funding, shape its corporate culture, attract top talent, and enhance its overall reputation.however, many nascent startups and founders face considerable challenges due to a lack of specialized knowledge and established networks. Successfully establishing a presence in a new ecosystem while together developing a groundbreaking medication is a daunting and time-consuming task.

Bayer’s Commitment: Resources and Expertise for US Expansion

Recognizing these hurdles, Bayer Pharmaceuticals in Basel has launched the “Bayer Co.Lab Connect” program to provide early-stage startups with the resources and specialized knowledge necessary to maximize their impact in the US market. The program also aims to foster a strong relationship between these startups and Bayer itself.

Switzerland has a lively startup ecosystem, especially in the area of life sciences. The networking of the flourishing Swiss startup scene with the unique ecosystem in the Kendall Square in Cambridge, with leading research institutions that are connected to Harvard and the one, a successful venture capital company, and also our Bayer Research and Innovation center and the Bayer Co.lab Cambridge, will create and accelerate new opportunities for groundbreaking medication of the future.
Dr. Jürgen Eckhardt, Head of Buisness Development & Licensing at Bayer Pharmaceuticals and Head of Leps

Accessing the Boston-Cambridge Biotech Hub

Through strategic partnerships with Superlab Suisse, a leading laboratory provider in Switzerland, and with the support of innovation-focused organizations like curie.bio,Goodwin,and Danforth Advisors,Bayer Co.lab Connect Basel facilitates access to the vibrant Boston-Cambridge ecosystem. This access provides Swiss biotech entrepreneurs and startups with direct connections to premier laboratory and office space providers, as well as invaluable expert guidance and mentorship tailored specifically for the US market.

The Boston-cambridge area is a global epicenter for biotechnology, boasting a high concentration of research institutions, pharmaceutical companies, and venture capital firms. Such as, Kendall Square, often referred to as “the most innovative square mile on the planet,” is home to numerous biotech giants and startups, fostering a highly competitive and collaborative surroundings.

We provide laboratories for life science companies in Switzerland and abroad-and thus help excellent companies. Due to the partnership with Bayer Co.Lab, we strengthen the Swiss Boston connection and open Swiss science entrepreneurs access to first-class mentorship, global presence and the necessary thrust to accelerate their success.
XI Zhang, founder and CEO of superlab Suisse AG

Curie.Bio’s Role: Empowering Founders and Accelerating Innovation

Curie.Bio emphasizes the importance of empowering founders to focus on their core mission: developing groundbreaking medications that can transform patient lives. Their goal is to provide biotech entrepreneurs with the expertise, resources, and capital they need to build robust pharmaceutical companies without relinquishing ownership or control.

We at Curie.Bio are convinced that founders should have freedom to concentrate on the essentials – the development of pioneering medication that can change the life of patients. Our goal is to provide biotech entrepreneurs the expertise, the resources and capital they need to build solid pharmaceutical companies without losing ownership and control. Through the partnership with Bayer Co.Lab Connect in Basel, we promote a dynamic environment in which young biotech startups have access to first-class mentors, important infrastructure and strategic industry connections. This collaboration is about clearing the hurdles for founders out of the way and ensuring that they receive the necessary support to promote their innovations quickly, efficiently and with scientific excellence.
nina Kreymborg, SVP, CSO Partner Team at Curie.Bio

Exclusive Opportunities: Bayer Co.Lab Portfolio and bio International Recognition

A select Swiss startup will be granted the opportunity to join Bayer Co.Lab’s prestigious portfolio and receive recognition at a Bayer-sponsored event during the Bio International Convention in 2025. This convention is one of the largest and most influential gatherings in the biotechnology industry, attracting thousands of attendees from around the globe.

Tailored Support: A Pathway to Clinical Maturity

The chosen Swiss startup will benefit from access to a fully equipped facility at Superlab Suisse in Basel, as well as the resources of Bayer Co.lab Cambridge, a global community of like-minded entrepreneurs. Furthermore, they will receive support from Bayer experts across various disciplines and facilitated connections to key partners within the ecosystem – all without any obligations. This customized approach ensures that startups can thrive in a supportive environment, accelerating the journey of their innovations towards clinical maturity. This is crucial, as the average cost to bring a new drug to market can exceed $2.6 billion, according to a study by the Tufts Center for the Study of Drug Development.